EHA 2021 | New approaches for AML patients who are not candidates for intensive therapy
Stéphane de Botton
• 14 Jun 2021
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses novel treatment approached for patients with acute myeloid leukemia (AML) who are not candidates for intensive therapy. Dr de Botton highlights data on IDH2 inhibitors and on the IDH1 inhibitor olutasidenib, and comments on the need for more Phase II trials in this patient population. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
